Clinical trials: Cancer Colonic
Oesophageal Squamous Cell Carcinoma, Gastric Cancer
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)
The study is a phase 2 non-randomized, open-label, multi-cohort, multi-center study assessing the clinical benefit of SAR444245 (THOR-707) combined with other anticancer therapies for the treatment of participants aged 18 years…
- Conditions
- Oesophageal Squamous Cell Carcinoma, Gastric Cancer, Hepatocellular Carcinoma, Colorectal Cancer
- Trial name
- NCT05104567
- Testing
- THOR-707, Pembrolizumab, Cetuximab
- Where
- 29 sites in United States, Belgium and 7 more
- Volunteers
- 138 people
- Sponsor
- Sanofi
Colorectal Carcinoma
A Study of Irinotecan, Levofolinate, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab (IMC-1121B)
The primary objective of this study is to investigate the safety and tolerability of the anti-vascular endothelial growth factor receptor-2 (anti-VEGFR-2) monoclonal antibody Ramucirumab (IMC-1121B) in combination with…
- Trial name
- NCT01286818
- Testing
- Ramucirumab (IMC-1121B), Irinotecan, levofolinate
- Where
- 3 sites in Japan
- Volunteers
- 6 people
- Sponsor
- Eli Lilly and Company
Colorectal Cancer
Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
PURPOSE: This randomized phase III trial is studying cetuximab and/or bevacizumab when given together with combination chemotherapy to compare how well they work in treating patients with metastatic colorectal cancer.
- Trial name
- NCT00265850
- Testing
- bevacizumab, cetuximab, FOLFOX or
- Where
- 683 sites in United States, Canada
- Volunteers
- 2,334 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Colon Cancer
Genotype-Directed Study Of Irinotecan Dosing In FOLFIRI + BevacizumabTreated Metastatic Colorectal Cancer
This study involves standard combination chemotherapy treatment for colon cancer, 5-Fluorouracil (5FU), leucovorin and irinotecan (known as FOLFIRI), plus bevacizumab (Avastin).
- Trial name
- NCT02138617
- Testing
- 5-Fluorouracil, Leucovorin, Irinotecan
- Where
- 7 sites in United States
- Volunteers
- 100 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Metastatic Colorectal Cancer
Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors
The primary purpose of the phase Ib is to estimate the MTD/RPD2 and of the phase II is to assess the anti-tumor activity of MEK162 in combination with panitumumab.
- Trial name
- NCT01927341
- Testing
- MEK162, Panitumumab
- Where
- 8 sites in United States, Belgium and 5 more
- Volunteers
- 53 people
- Sponsor
- Pfizer
Colon Cancer, Rectum Cancer
Irinotecan and Cetuximab for Colorectal Cancer as Second Line Therapy
Research Hypothesis: Subjects in the study population who are treated with cetuximab in combination with irinotecan will have higher response rates than subjects treated with irinotecan alone.
- Trial name
- NCT00336856
- Testing
- Cetuximab, Irinotecan
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- University of Pittsburgh
Non Small Cell Lung Cancer, Urothelial Carcinoma
Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors
In this phase I first-in-humans-study a vaccine consisting of arginase-1 (ARG1) peptides and the adjuvant Montanide ISA-51 will be tested in ten patients with metastatic solid tumors.
- Conditions
- Non Small Cell Lung Cancer, Urothelial Carcinoma, Malignant Melanoma, Ovarian Cancer
- Trial name
- NCT03689192
- Testing
- ARG1-18,19,20
- Where
- Denmark
- Volunteers
- 13 people
- Sponsor
- Herlev Hospital
Colorectal Cancer
Strategies and Opportunities to Stop Colon Cancer in Priority Populations
Only an estimated 50 million US adults aged 50-75 are up-to-date on colorectal cancer (CRC) screening according to guidelines set by the federal government.
- Trial name
- STOPCRC (NCT01742065)
- Testing
- Auto Plus
- Where
- 8 sites in United States
- Volunteers
- 62,155 people, healthy volunteers welcome
- Sponsor
- Kaiser Permanente
Colorectal Cancer
U01 CRC Project for Vietnamese Americans
Colorectal cancer (CRC) is the second most commonly diagnosed cancer and the third highest cause of mortality in Vietnamese and Asian Americans.
- Trial name
- NCT03413605
- Testing
- A Multilevel CBPR Intervention
- Where
- 2 sites in United States
- Volunteers
- 801 people
- Sponsor
- Temple University
Colon Cancer, Fragility
Prehabilitation of Frail Surgical Cancer Patients Using Remote Ischemic Preconditioning
This project will examine the efficacy of a simple, cost-effective, non-invasive intervention, called remote ischemic preconditioning (RIPC), to reduce frailty in pre-surgical, frail, elderly patients with colon cancer.
- Conditions
- Colon Cancer, Fragility, Prehabilitation, Surgery
- Trial name
- Prehab (NCT03853473)
- Testing
- Remote Ischemic Preconditioning
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Medical College of Wisconsin
Non-small Cell Lung Cancer, Pancreatic Cancer
Study to Compare the Effects of Repeated Doses of an Investigational New Drug and a Placebo on Appetite in Advanced Cancer and Anorexia
Study to compare the effects of the investigational new drug (PF-06946860) and a placebo on appetite and to find out how participants with advanced cancer and anorexia feel after receiving repeated subcutaneous (SC-injected under…
- Conditions
- Non-small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer, Prostate Cancer
- Trial name
- NCT04803305
- Testing
- PF-06946860
- Where
- 33 sites in United States, Canada
- Volunteers
- 18 people
- Sponsor
- Pfizer
Colon Cancer
Miralax (PEG 3350) vs. Golytely as Bowel Preparation for Screening Colonoscopy
A major limitation to the widespread acceptance of colonoscopy as a procedure to screen for colorectal cancer is the laxative preparation. Phosphate-based preps (e.g.
- Trial name
- NCT01170754
- Testing
- PEG-3350 and Gatorade, Golytely 4 liters
- Where
- United States
- Volunteers
- 136 people, healthy volunteers welcome
- Sponsor
- Temple University
Metastatic Colorectal Cancer (mCRC)
Assessing a Regorafenib-irinotecan Combination Versus Regorafenib Alone in Metastatic Colorectal Cancer Patients
Patients with metastatic colorectal cancer (mCRC) who have received all approved standard treatments (except Regorafenib and Lonsurf) no longer have treatment options available while maintaining a good performance status which…
- Trial name
- NEXT-REGIRI (NCT03829462)
- Testing
- Regorafenib, Irinotecan
- Where
- 11 sites in France
- Volunteers
- 377 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Gastrointestinal Cancers, Cholangiocarcinoma
Study of [18F]FAPI-74 PET in Patients With Gastrointestinal Cancers
Prospective, multi-center, open label, non-randomized clinical trial to assess efficacy of [18F]FAPI-74 to detect FAP expressing cells in patients diagnosed with gastrointestinal cancers, including hepatocellular carcinoma…
- Conditions
- Gastrointestinal Cancers, Cholangiocarcinoma, Gastric Cancer, Colorectal Cancer
- Trial name
- 18F-FAPI-74 GI (NCT05641896)
- Testing
- [18F]FAPI-74 PET/CT
- Where
- 6 sites in United States
- Volunteers
- 112 people
- Sponsor
- SOFIE
Advanced Malignancies, Metastatic Cancer
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
The purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01876 when given in combination with immune therapies in subjects with advanced or metastatic malignancies.
- Trial name
- NCT03126110
- Testing
- INCAGN01876, Nivolumab, Ipilimumab
- Where
- 38 sites in United States, Australia and 2 more
- Volunteers
- 145 people
- Sponsor
- Incyte Biosciences International Sàrl
Colorectal Cancer, Stomach Disease
Screening for Stomach Diseases and Colorectal Neoplasms With the Fecal Testing
1. The abundant results from this trial will be helpful for assessing the feasibility of increasing stool sampling and shortening screening interval in population setting for lower and upper gastrointestinal tract lesions, their…
- Trial name
- NCT01741363
- Testing
- FIT(Eiken OC-Sensor) Two-day sampling, FIT(Eiken OC-Sensor) One-year interval, FIT(Eiken OC-Sensor) One-day sampling
- Where
- Taiwan
- Volunteers
- 99,314 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Non-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer
MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors
Brain metastases are the most common intracranial malignancy occurring in 20-40% of all cancers, and the presence of CNS metastases is associated with a poor prognosis.
- Conditions
- Non-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer, Breast Cancer, Cancer of Breast
- Trial name
- NCT02669914
- Testing
- MEDI4736
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Washington University School of Medicine
Rectal Cancer, Cancer of the Rectum
5-Fluorouracil, Bevacizumab, and Radiation Followed by Modified FOLFOX6 and Bevacizumab in Stage II/III Rectal Cancer
This phase II trial will investigate the combination of adjuvant 5-fluorouracil, radiation, and bevacizumab in patients with stage II and III rectal cancer, followed by FOLFOX6 and bevacizumab.
- Conditions
- Rectal Cancer, Cancer of the Rectum, Colorectal Cancer
- Trial name
- NCT00308516
- Testing
- 5-Fluorouracil, Bevacizumab, Radiation Therapy
- Where
- 14 sites in United States
- Volunteers
- 66 people
- Sponsor
- SCRI Development Innovations, LLC
Colorectal Cancer (CRC)
Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation
The aim of the study is to compare progression-free survival (PFS) in previously treated participants with Kirsten rat sarcoma (KRAS) p.G12C mutated colorectal cancer (CRC) receiving sotorasib 240 mg once daily (QD) and…
- Trial name
- CodeBreak300 (NCT05198934)
- Testing
- Sotorasib, Panitumumab, Trifluridine and Tipiracil
- Where
- 105 sites in United States, Australia and 10 more
- Volunteers
- 160 people
- Sponsor
- Amgen
Colorectal Cancer
Neoadjuvant Chemoradiotherapy and Adjuvant Chemotherapy in Treating Patients Who Are Undergoing Surgical Resection for Locally Advanced Rectal Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00081289
- Testing
- Radiation Therapy, Capecitabine 1650 mg/m^2/day, Capecitabine 1200 mg/m^2/day
- Where
- 5 sites in United States
- Volunteers
- 146 people
- Sponsor
- Radiation Therapy Oncology Group